Holen Sie sich die Stockscreener-App
0.6603
5.54%
-0.0387
Handel nachbörslich:
.65
-0.0103
-1.56%
Schlusskurs vom Vortag:
$0.699
Offen:
$0.699
24-Stunden-Volumen:
31,816
Relative Volume:
0.17
Marktkapitalisierung:
$91.99M
Einnahmen:
$78.46M
Nettoeinkommen (Verlust:
$2.75M
KGV:
66.03
EPS:
0.01
Netto-Cashflow:
$-12.42M
1W Leistung:
-10.38%
1M Leistung:
+34.84%
6M Leistung:
+65.07%
1J Leistung:
-11.39%
1-Tages-Spanne:
$0.6551
$0.6999
1-Wochen-Bereich:
$0.64
$0.73
52-Wochen-Spanne:
$0.331
$0.8325
Xtant Medical Holdings Inc Stock (XTNT) Company Profile
Firmenname
Xtant Medical Holdings Inc
Sektor
Branche
Telefon
406-388-0480
Adresse
664 Cruiser Lane, Belgrade, MT
Vergleichen Sie XTNT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XTNT
Xtant Medical Holdings Inc
|
0.6603 | 102.65M | 78.46M | 2.75M | -12.42M | 0.01 |
|
ABT
Abbott Laboratories
|
133.58 | 228.44B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
105.26 | 154.60B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
382.64 | 143.93B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
82.98 | 103.43B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.22 | 43.99B | 5.54B | 4.18B | 623.10M | 7.00 |
Xtant Medical Holdings Inc Stock (XTNT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-12-05 | Eingeleitet | BTIG Research | Buy |
| 2018-11-15 | Bestätigt | Maxim Group | Buy |
| 2018-02-14 | Bestätigt | Maxim Group | Buy |
Xtant Medical Holdings Inc Aktie (XTNT) Neueste Nachrichten
Xtant Medical Unveils OsteoFactor Pro for Bone Healing - Precedence Research
Xtant Medical (NYSEAMERICAN:XTNT) Share Price Crosses Above 200 Day Moving Average – Here’s Why - Defense World
Xtant Medical launches OsteoFactor Pro for bone repair By Investing.com - Investing.com South Africa
Xtant Medical Announces the Launch of OsteoFactor Pro™ - Ortho Spine News
Xtant Medical Holdings, Inc. Announces the Launch of OsteoFactor Pro - marketscreener.com
Xtant Medical launches OsteoFactor Pro for bone repair - Investing.com Australia
Xtant Medical Introduces First-Ever Complete Orthobiologic Portfolio with New Bone Growth Technology - Stock Titan
Xtant Medical’s Earnings Call Highlights Growth and Optimism - TipRanks
Earnings call transcript: Xtant Medical Q1 2025 shows revenue growth and stock surge - Investing.com Nigeria
Xtant Medical outlines 8–11% revenue growth target for 2025 as company completes vertical integration and launches new products - MSN
Xtant Medical (XTNT) Files to Sell Over 73 Million Shares of Com - GuruFocus
Xtant Medical Holdings, Inc. (AMEX:XTNT) Q1 2025 Earnings Call Transcript - Insider Monkey
Xtant Medical’s Q1 2025 revenue increases 18% to USD 32.9M - Medical Buyer
Xtant Medical Reports Strong Q1 2025 Results - TipRanks
Xtant Medical Q1 2025 Earnings Call Transcript - MarketBeat
Xtant Medical Reports First Quarter 2025 Financial Results - Yahoo Finance
Xtant Medical Holdings Inc (XTNT) Q1 2025: Everything You Need T - GuruFocus
Xtant Medical (XTNT) Projected to Post Quarterly Earnings on Monday - Defense World
Xtant Medical Sets Q1 2025 Earnings Date: MedTech Leader to Discuss Surgical Solutions Growth on May 12 - Stock Titan
Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Shares Acquired by Renaissance Technologies LLC - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
How to interpret Xtant Medical Holdings Inc (XTNT)’s stock chart patterns - uspostnews.com
Xtant Medical Launches Trivium™ Advanced Bone Graft for Superior Performance - GuruFocus
Analysts Offer Insights on Healthcare Companies: Viatris (VTRS), Xtant Medical Holdings (XTNT) and Medtronic (MDT) - The Globe and Mail
Xtant Medical Holdings Inc (AMEX: XTNT) Has Great Upside Potential - stocksregister.com
Xtant Medical announces secondary private sale of existing shares - Medical Buyer
Xtant Medical Ends Investor Agreement After Share Sale - TipRanks
Xtant Medical secures investor support, projects Q1 revenue growth By Investing.com - Investing.com South Africa
Xtant Medical Announces Secondary Private Sale of Existing Shares by OrbiMed and Preliminary First Quarter 2025 Revenue Growth of 18% to 19% - Ortho Spine News
Xtant Medical Announces Secondary Private Sale Of Existing Shares By Orbimed - marketscreener.com
Major Shakeup: OrbiMed Sells Entire Xtant Medical Stake as Revenue Surges 19% - Stock Titan
Orbimed advisors sells Xtant Medical stock for $30.7 million - Investing.com
Xtant Medical shares change hands in major stock purchase - Investing.com
Xtant Medical shares change hands in major stock purchase By Investing.com - Investing.com India
Xtant Medical Expands Product Portfolio with Launch of its own Viable Bone Matrix, OsteoVive(R) Plus - ACCESS Newswire
Xtant Medical (NYSEAMERICAN:XTNT) Shares Cross Above Two Hundred Day Moving Average – Time to Sell? - Defense World
Spinal Fusion Device Market Forecast Report and Company Analysis 2025-2033 Featuring Medtronic, Stryker, Zimmer Biomet, Orthofix Medical, NuVasive, Globus Medical, Xtant Medical, and Alphatec – Ortho Spine News - OrthoSpineNews
Spinal Fusion Device Market Forecast Report and Company - GlobeNewswire
Xtant Medical (NYSEAMERICAN:XTNT) Share Price Passes Above Two Hundred Day Moving Average – Time to Sell? - Defense World
Xtant Medical Faces Risk of Share Distribution by Major Stakeholder, Threatening Stock Stability - MSN
Xtant Medical Holdings, Inc. (AMEX:XTNT) Q4 2024 Earnings Call Transcript - Insider Monkey
Xtant Medical’s Earnings Call: Mixed Outlook with Growth Plans - TipRanks
Earnings call transcript: Xtant Medical Q4 2024 misses EPS, stock drops - Investing.com India
Earnings call transcript: Xtant Medical Q4 2024 misses EPS, stock drops By Investing.com - Investing.com South Africa
Xtant Medical stock target cut to $2 at BTIG, retains buy rating By Investing.com - Investing.com South Africa
Xtant Medical stock target cut to $2 at BTIG, retains buy rating - Investing.com
Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Short Interest Update - Defense World
Xtant Medical Reports Strong 2024 Revenue Growth - TipRanks
Finanzdaten der Xtant Medical Holdings Inc-Aktie (XTNT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.36%
1.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):